Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.
Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, Cinieri S, Curigliano G, Del Mastro L, De Placido S, Fabi A, Fortunato L, Generali D, Gennari A, Gori S, Grandi G, Guarneri V, Klinger M, Livi L, Marchiò C, Palumbo I, Panizza P, Pravettoni G, Pruneri G, Puglisi F, Sapino A, Tinterri C, Turchetti D, De Laurentiis M.
Zambelli A, et al. Among authors: fortunato l.
Cancer Treat Rev. 2024 Nov;130:102815. doi: 10.1016/j.ctrv.2024.102815. Epub 2024 Aug 21.
Cancer Treat Rev. 2024.
PMID: 39208751
Free article.
Review.